Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00082589
Status:
COMPLETED
Last Update Posted:
2020-12-22
First Post:
2004-05-12
Brief Title:
The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
A Randomized Double-Blind Multi-CenterStudy Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patients With Left Ventricular Systolic Dysfunction EF Less Than or Equal to 35 and Mild to Moderate Heart Failure
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REMODEL
Brief Summary:
The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None